welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
researchers
Eugene Gerner, PhD
Researcher Director
Gastrointestinal Cancer Program
Arizona Cancer Center
Tucson, Arizona, United States
CEO, Cancer Prevention Pharmaceuticals (CPP)
Cancer Prevention Pharmaceuticals (CPP) is a company in the late stages of developing drugs and drug combinations to treat people with risk factors for cancer. Some of these people have genetic risk factors, such as defects in the adenomatous poly posits coli tumor suppressor gene which cause the familial adenomatous polyposis (FAP) syndrome. Others have sporadic risk factors, such as prior colorectal cancer or neuroblastoma with amplified copies of the MYCN oncogene. CPP is also developing companion diagnostics for its drug therapies.
expertly curated content related to this topic
-
Arnold J. Markowitz, MDArnold J. Markowitz is a board-certified...
-
James Yoo, MDDr. James Yoo, MD, is Chief of the Divis...
-
St. Mark’s Hospital/Polyposis RegistryPatient Resources: Polyposis Regist...
-
Stanford HospitalThe Cancer Genetics Clinic is part of St...
-
David M. Kastenberg, MDInterests: Inherited Colorectal Cancer -...
-
Colon cancer gene mutation found in 18th century mummyA gene mutation associated with colon ca...
-
Francesc BalaguerFrancesc Balaguer is a researcher at Hos...